SCHEMBL1937260

SCHEMBL1937260

FC(F)(F)c1ccc(CNCC2CN(Cc3ccccc3)CC2c2ccc(Cl)c(Cl)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.47
BCHE P06276 2/20 0.47
BACE1 P56817 2/20 0.47
KCNH2 Q12809 2/20 0.41
TMEM97 Q5BJF2 2/20 0.41
TACR1 P25103 5/20 0.41
RORC P51449 1/20 0.41
HIF1A Q16665 1/20 0.40
EPAS1 Q99814 1/20 0.40
TACR2 P21452 4/20 0.40
CCR5 P51681 2/20 0.40
MCHR1 Q99705 1/20 0.40
SIGMAR1 Q99720 2/20 0.39
KDM1A O60341 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
CXCR4 P61073 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1937452 0.88 CCR5 (0.53) ACHEBCHEBACE1HIF1AEPAS1
SCHEMBL3031891 0.87 HIF1A (0.43) ACHEBCHEBACE1TACR1RORC
SCHEMBL3019414 0.81 TACR1 (0.39) TACR1RORCHIF1AEPAS1TACR2
SCHEMBL3035831 0.81 RORC (0.47) KCNH2RORCCCR5MCHR1SIGMAR1
SCHEMBL3035832 0.81 RORC (0.47) KCNH2RORCCCR5MCHR1SIGMAR1
SCHEMBL3025795 0.81 RORC (0.49) KCNH2RORCCCR5MCHR1SIGMAR1
SCHEMBL3025794 0.81 RORC (0.49) KCNH2RORCCCR5MCHR1SIGMAR1
SCHEMBL3032336 0.81 TACR1 (0.40) TACR1RORCTACR2CCR5SIGMAR1
SCHEMBL3032339 0.81 TACR1 (0.40) TACR1RORCTACR2CCR5SIGMAR1
SCHEMBL3252962 0.80 KCNH2 (0.43) KCNH2TACR1RORCTACR2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364295-B1 3-(BENZYLAMINO)-PYRROLIDINE DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-02-27 EP disclosed
US-8293770-B2 Pyrrolidine derivatives as NK-3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-10-23 US disclosed
US-8022099-B2 N-benzyl pyrrolidine derivatives HOFFMANN-LA ROCHE INC. (US) 2011-09-20 US disclosed
EP-2364295-A1 3-(BENZYLAMINO)-PYRROLIDINE DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-09-14 EP disclosed
EP-2331500-A1 PYRROLIDINE N-BENZYL DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-06-15 EP disclosed
US-20100168088-A1 PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 US disclosed
WO-2010060703-A1 3-(BENZYLAMINO)-PYRROLIDINE DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-06-03 WO disclosed
US-20100113424-A1 N-BENZYL PYRROLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 US disclosed
WO-2010040663-A1 PYRROLIDINE N-BENZYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168088-A1 PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS OPRK1, OPRL1, OPRD1 ACHE 907/4885BCHE 3516/4885BACE1 2431/4885
US-20100113424-A1 N-BENZYL PYRROLIDINE DERIVATIVES OPRK1, OPRD1, OPRL1 ACHE 362/4885BCHE 1249/4885BACE1 1032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.